Biotech | May 05, 2022
Mediso acquires nuclear medicine supplier Bartec Technologies
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Supply increase to help meet growing global demand
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Subscribe To Our Newsletter & Stay Updated
